VANI sentiment intelligence

Vivani Medical (NASDAQ: VANI) Targets August Human Trial For Semaglutide Implant Following Novo Nordisk Evaluation Deal

Vivani Medical has entered an agreement with Novo Nordisk for the evaluation of its semaglutide drug implant, NPM-139, designed for chronic weight management. The company also received ethics committee approval to begin its Phase 1 human clinical trial (SLIM-1) in Australia in Au

Tone

Positive 74/100

Event

Deals and strategy

Published

16 Jul 2026 17:12

Source

Foreign Policy Journal

Vivani Medical says first SLIM-1 dosing expected in August 2026 after CEO presentation

Vivani Medical (VANI) announced that the first dosing of its SLIM-1 product is anticipated in August 2026. This information was disclosed during a presentation by CEO Dr. Adam Mendelsohn at the Emerging Growth Conference in New York on July 15, 2026. The details were provided in

Tone

Positive 66/100

Event

Market update

Published

16 Jul 2026 12:12

Source

TradingView

Vivani Medical at emerging growth conference: implant push gains traction By Investing.com

Vivani Medical (VANI) presented its implant-based drug delivery platform at the Emerging Growth Conference, highlighting new interest from Novo Nordisk for evaluating its semaglutide implants and progress towards its first semaglutide study. The company plans to begin its SLIM-1

Tone

Positive 90/100

Event

Market update

Published

16 Jul 2026 04:11

Source

Investing.com South Africa

Vivani Medical (VANI) Emerging Growth Conference Summary

Vivani Medical presented at the Emerging Growth Conference, highlighting a new agreement with Novo Nordisk for its semaglutide implant and preparing to initiate the SLIM-1 clinical trial in August. The implant offers infrequent administration, steady drug release, and addresses a

Tone

Positive 74/100

Event

Market update

Published

16 Jul 2026 04:11

Source

Quartr

Vivani Medical to Present at the Emerging Growth Conference on July 15, 2026

Vivani Medical, Inc. announced that it will present at the Emerging Growth Conference on July 15, 2026, at 4:10 p.m. Eastern Time. CEO Adam Mendelsohn will provide a company update on their miniature, GLP-1 drug implants designed for once- or twice-yearly administration for metab

Tone

Positive 65/100

Event

Market update

Published

15 Jul 2026 00:14

Source

GlobeNewswire

A tiny GLP-1 implant is the latest bet to help patients maintain their weight loss

Vivani Medical is developing a tiny GLP-1 implant designed to help patients maintain weight loss long-term, addressing issues like injection fatigue and treatment adherence common with existing GLP-1 drugs. The implant, containing semaglutide, is intended as a maintenance therapy

Tone

Positive 63/100

Event

Market update

Published

12 Jul 2026 11:11

Source

CNBC

H.C. Wainwright reiterates Vivani Medical stock rating on Novo deal

H.C. Wainwright has reiterated a Buy rating and a $3.50 price target for Vivani Medical (NASDAQ:VANI) following the company's agreement with Novo Nordisk to evaluate NPM-139, Vivani's semaglutide drug implant for chronic weight management. This agreement is seen as external valid

Tone

Positive 72/100

Event

Analyst action

Published

10 Jul 2026 12:39

Source

Investing.com

H.C. Wainwright reiterates Vivani Medical stock rating on Novo deal By Investing.com

H.C. Wainwright has reiterated its Buy rating and a $3.50 price target for Vivani Medical (NASDAQ:VANI) following the company's agreement with Novo Nordisk. Vivani Medical's stock surged 24% over the past week after announcing a deal for Novo Nordisk to evaluate NPM-139, Vivani’s

Tone

Positive 70/100

Event

Analyst action

Published

10 Jul 2026 12:10

Source

Investing.com Australia

Analysts Set Expectations for Vivani Medical Q1 Earnings

HC Wainwright initiated Q1 2027 earnings estimates for Vivani Medical (NASDAQ:VANI) at a loss of $0.07 per share, maintaining a Buy rating and a $3.50 price target. Despite this, the broader analyst view is more cautious with an average "Hold" rating and a $3.75 price target. The

Tone

Positive 62/100

Event

Analyst action

Published

10 Jul 2026 12:10

Source

MarketBeat

Maxim Group Maintains Vivani Medical(VANI.US) With Buy Rating, Maintains Target Price $4

Maxim Group has reiterated its Buy rating for Vivani Medical (VANI.US) and maintained its target price at $4. This indicates continued confidence from the firm in the company's performance and future prospects.

Tone

Positive 72/100

Event

Analyst action

Published

10 Jul 2026 10:39

Source

Moomoo

Vivani Medical (VANI) Receives a Buy from Lake Street

Tone

Positive 66/100

Event

Market update

Published

08 Jul 2026 13:06

Source

The Globe and Mail

Lake Street Maintains Vivani Medical(VANI.US) With Buy Rating, Maintains Target Price $4

Lake Street maintained its Buy rating on Vivani Medical (VANI.US) and kept its target price at $4. This indicates continued confidence in the company's prospects from the analyst firm.

Tone

Positive 71/100

Event

Analyst action

Published

07 Jul 2026 22:10

Source

Moomoo

Vivani Flat on Hookup with Novo

Vivani Medical, Inc. announced a new agreement allowing Novo Nordisk to evaluate its semaglutide drug implant, NPM-139, for chronic weight management. Vivani expects to start a Phase 1 study for NPM-139 in mid-2026, comparing it to Wegovy® injections. This collaboration highlight

Tone

Positive 67/100

Event

Guidance

Published

07 Jul 2026 16:42

Source

Baystreet.ca

ClearOne (Nasdaq: CLRO) sets Cortigent merger, Vivani majority stake and $10–15M raise

ClearOne, Inc. has announced a definitive merger agreement to acquire Cortigent, Inc., a wholly-owned subsidiary of Vivani Medical, Inc. Vivani will receive 12.5 million ClearOne shares, subsequently owning 59.4%–67.5% of the combined company, which will be renamed Cortigent Hold

Tone

Positive 64/100

Event

Deals and strategy

Published

06 Jul 2026 20:31

Source

Stock Titan